This cohort included 240 patients with NSCLC treated with anti‐PD‐L1 alone or in combination with anti‐cytotoxic T‐cell lymphocyte‐4 (anti‐CTLA‐4) therapeutic scheme. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.